A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer
Open Access
- 30 April 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 334, 335-352
- https://doi.org/10.1016/j.jconrel.2021.04.034
Abstract
No abstract availableThis publication has 61 references indexed in Scilit:
- Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activityBiomaterials, 2013
- Polymeric micelle stabilityNano Today, 2012
- Tidying up loose ends: the role of polynucleotide kinase/phosphatase in DNA strand break repairTrends in Biochemical Sciences, 2011
- Harnessing synthetic lethal interactions in anticancer drug discoveryNature Reviews Drug Discovery, 2011
- Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factorsBMC Cancer, 2011
- Searching for synthetic lethality in cancerCurrent Opinion in Genetics & Development, 2011
- Tenets of PTEN Tumor SuppressionCell, 2008
- Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI‐124 in a mouse melanoma tumor modelImmunology & Cell Biology, 2008
- Phosphatase Protein Homologue to Tensin Expression and Phosphatidylinositol-3 Phosphate Kinase Mutations in Colorectal CancerCancer Research, 2005
- Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of PaclitaxelClinical Cancer Research, 2005